Which companies overlap with Grupo de Estudos Multicentricos em Onco-Hematologia's portfolio?

Top competitors by shared drug class: Celgene, Gruppo Italiano Studio Linfomi.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/grupo-de-estudos-multicentricos-em-onco-hematologia.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Grupo de Estudos Multicentricos em Onco-Hematologia — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Grupo de Estudos Multicentricos em Onco-Hematologia pipeline: 0 marketed, 0 filed, 5 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 5 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Thalidomide, Melphalan, Prednisone	Thalidomide, Melphalan, Prednisone	phase 3	Combination chemotherapy with immunomodulatory agent	Multiple targets: cereblon (thalidomide), DNA (melphalan), glucocorticoid receptor (prednisone)	Oncology
Bortezomib, cyclophosphamide, thalidomide, dexamethasone	Bortezomib, cyclophosphamide, thalidomide, dexamethasone	phase 3	Combination chemotherapy regimen (proteasome inhibitor + alkylating agent + immunomodulatory agent + corticosteroid)	Proteasome (bortezomib); DNA (cyclophosphamide); TNF-α pathway and cereblon (thalidomide); glucocorticoid receptor (dexamethasone)	Oncology
Thalidomide, Cyclophosphamide, Dexamethasone	Thalidomide, Cyclophosphamide, Dexamethasone	phase 3	Glutamic acid derivative, Alkylating agent, Corticosteroid	TNF-alpha, DNA	Oncology
Thalidomide plus dexamethasone	Thalidomide plus dexamethasone	phase 3	Immunomodulatory agent plus corticosteroid	Cereblon (CRBN), glucocorticoid receptor	Oncology
Thalidomide, Dexamethasone	Thalidomide, Dexamethasone	phase 3	Anti-inflammatory, Immunomodulator	TNF-alpha	Oncology

Therapeutic area mix

Oncology · 5

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Celgene · 1 shared drug class
Gruppo Italiano Studio Linfomi · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Grupo de Estudos Multicentricos em Onco-Hematologia:

Cite this brief

Drug Landscape (2026). Grupo de Estudos Multicentricos em Onco-Hematologia — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/grupo-de-estudos-multicentricos-em-onco-hematologia. Accessed 2026-05-17.